Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Progress towards a Nordic standard for the investigation of hematuria: 2019.

Malmström PU, Skaaheim Haug E, Boström PJ, Gudjónsson S, Bjerggaard Jensen J.

Scand J Urol. 2019 Jan 14:1-6. doi: 10.1080/21681805.2018.1555187. [Epub ahead of print]

PMID:
30636472
2.

Cell-type specific CD73 expression is an independent prognostic factor in bladder cancer.

Koivisto M, Tervahartiala M, Kenessey I, Jalkanen S, Boström PJ, Salmi M.

Carcinogenesis. 2018 Nov 3. doi: 10.1093/carcin/bgy154. [Epub ahead of print]

PMID:
30395172
3.

ANO7 is associated with aggressive prostate cancer.

Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J.

Int J Cancer. 2018 Nov 15;143(10):2479-2487. doi: 10.1002/ijc.31746. Epub 2018 Sep 22.

PMID:
30157291
4.

Tournament leave-pair-out cross-validation for receiver operating characteristic analysis.

Montoya Perez I, Airola A, Boström PJ, Jambor I, Pahikkala T.

Stat Methods Med Res. 2018 Aug 20:962280218795190. doi: 10.1177/0962280218795190. [Epub ahead of print]

PMID:
30126322
5.

11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial).

Salminen A, Jambor I, Merisaari H, Ettala O, Virtanen J, Koskinen I, Veskimae E, Sairanen J, Taimen P, Kemppainen J, Minn H, Boström PJ.

Cancer Imaging. 2018 Aug 2;18(1):25. doi: 10.1186/s40644-018-0158-4.

6.

Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment.

Nurminen P, Ettala O, Seppänen M, Taimen P, Boström PJ, Kaipia A.

BJU Int. 2019 Feb;123(2):246-251. doi: 10.1111/bju.14470. Epub 2018 Aug 12.

PMID:
29959824
7.

Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.

Knuuttila M, Mehmood A, Mäki-Jouppila J, Ryberg H, Taimen P, Knaapila J, Ettala O, Boström PJ, Ohlsson C, Venäläinen MS, Laiho A, Elo LL, Sipilä P, Mäkelä SI, Poutanen M.

Endocr Relat Cancer. 2018 Sep;25(9):807-819. doi: 10.1530/ERC-18-0148. Epub 2018 May 17.

PMID:
29773553
8.

Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study.

Knaapila J, Kallio H, Hakanen AJ, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Gunell M, Boström PJ.

BJU Int. 2018 Aug;122(2):203-210. doi: 10.1111/bju.14198. Epub 2018 Apr 6.

PMID:
29533507
9.

Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries.

Ylönen O, Jyrkkiö S, Pukkala E, Syvänen K, Boström PJ.

BJU Int. 2018 Sep;122(3):384-393. doi: 10.1111/bju.14148. Epub 2018 Mar 1.

PMID:
29460991
10.

New prostate cancer grade grouping system predicts survival after radical prostatectomy.

Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Hum Pathol. 2018 May;75:159-166. doi: 10.1016/j.humpath.2018.01.027. Epub 2018 Feb 13. No abstract available.

11.

Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort.

Knaapila J, Gunell M, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Hakanen AJ, Boström PJ.

Eur Urol Focus. 2017 Dec 20. pii: S2405-4569(17)30270-5. doi: 10.1016/j.euf.2017.12.001. [Epub ahead of print]

PMID:
29275146
12.

Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).

Jambor I, Kuisma A, Kähkönen E, Kemppainen J, Merisaari H, Eskola O, Teuho J, Perez IM, Pesola M, Aronen HJ, Boström PJ, Taimen P, Minn H.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):355-364. doi: 10.1007/s00259-017-3875-1. Epub 2017 Nov 16.

PMID:
29147764
13.

The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.

Seikkula HA, Kaipia AJ, Ryynänen H, Seppä K, Pitkäniemi JM, Malila NK, Boström PJ.

Int J Cancer. 2018 Mar 1;142(5):891-898. doi: 10.1002/ijc.31109. Epub 2017 Oct 31.

PMID:
29044563
14.

Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer.

Tervahartiala M, Taimen P, Mirtti T, Koskinen I, Ecke T, Jalkanen S, Boström PJ.

Sci Rep. 2017 Oct 4;7(1):12682. doi: 10.1038/s41598-017-12892-5.

15.

Non-muscle-invasive bladder cancer: a vision for the future.

Malmström PU, Agrawal S, Bläckberg M, Boström PJ, Malavaud B, Zaak D, Hermann GG.

Scand J Urol. 2017 Apr;51(2):87-94. doi: 10.1080/21681805.2017.1283359. Epub 2017 Feb 7. Review.

PMID:
28535714
16.

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.

J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.

17.

Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA.

Seikkula HA, Kaipia AJ, Rantanen ME, Pitkäniemi JM, Malila NK, Boström PJ.

Acta Oncol. 2017 Jul;56(7):971-977. doi: 10.1080/0284186X.2017.1288298. Epub 2017 Feb 13.

PMID:
28406044
18.

Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).

Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ.

J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. doi: 10.1002/jmri.25641. Epub 2017 Feb 6.

PMID:
28165653
19.

Erratum: Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.

Laajala TD, Seikkula H, Seyednasrollah F, Mirtti T, Boström PJ, Elo LL.

Sci Rep. 2017 Jan 19;7:40835. doi: 10.1038/srep40835. No abstract available.

20.

Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study.

Ginsburg SB, Algohary A, Pahwa S, Gulani V, Ponsky L, Aronen HJ, Boström PJ, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Taimen P, Villani R, Stricker P, Rastinehad AR, Jambor I, Madabhushi A.

J Magn Reson Imaging. 2017 Jul;46(1):184-193. doi: 10.1002/jmri.25562. Epub 2016 Dec 19.

21.

Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.

Laajala TD, Seikkula H, Seyednasrollah F, Mirtti T, Boström PJ, Elo LL.

Sci Rep. 2016 Nov 2;6:36161. doi: 10.1038/srep36161. Erratum in: Sci Rep. 2017 Jan 19;7:40835.

22.

Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.

Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH.

J Urol. 2016 Dec;196(6):1627-1633. doi: 10.1016/j.juro.2016.06.017. Epub 2016 Jun 14.

PMID:
27312316
23.

Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.

Lahdensuo K, Erickson A, Saarinen I, Seikkula H, Lundin J, Lundin M, Nordling S, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Mod Pathol. 2016 Dec;29(12):1565-1574. doi: 10.1038/modpathol.2016.154. Epub 2016 Aug 26.

24.

Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy.

Boström PJ, Mirtti T, van Rhijn B, Fleshner NE, Finelli A, Laato M, Jewett MA, Moore MJ, Sridhar S, Nurmi M, Tannock IF, Zlotta AR.

Bladder Cancer. 2016 Apr 27;2(2):263-272.

25.

Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy.

Boström PJ, Thoms J, Sykes J, Ahmed O, Evans A, van Rhijn BW, Mirtti T, Stakhovskyi O, Laato M, Margel D, Pintilie M, Kuk C, Milosevic M, Zlotta AR, Bristow RG.

Bladder Cancer. 2016 Jan 7;2(1):101-109.

26.

Correction: Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M.

PLoS One. 2016 Jun 21;11(6):e0158255. doi: 10.1371/journal.pone.0158255. eCollection 2016.

27.

Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method.

Ginsburg SB, Taimen P, Merisaari H, Vainio P, Boström PJ, Aronen HJ, Jambor I, Madabhushi A.

J Magn Reson Imaging. 2016 Dec;44(6):1405-1414. doi: 10.1002/jmri.25330. Epub 2016 Jun 10.

28.

Update on novel imaging techniques for the detection of lymph node metastases in bladder cancer.

Salminen AP, Jambor I, Syvanen KT, Bostrom PJ.

Minerva Urol Nefrol. 2016 Apr;68(2):138-49. Review.

29.

Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M.

PLoS One. 2016 May 19;11(5):e0155901. doi: 10.1371/journal.pone.0155901. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0158255.

30.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

31.

Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.

Alinezhad S, Väänänen RM, Ochoa NT, Vertosick EA, Bjartell A, Boström PJ, Taimen P, Pettersson K.

BMC Urol. 2016 Feb 29;16:10. doi: 10.1186/s12894-016-0128-8.

32.

Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction.

Merisaari H, Movahedi P, Perez IM, Toivonen J, Pesola M, Taimen P, Boström PJ, Pahikkala T, Kiviniemi A, Aronen HJ, Jambor I.

Magn Reson Med. 2017 Mar;77(3):1249-1264. doi: 10.1002/mrm.26169. Epub 2016 Feb 28.

PMID:
26924552
33.

Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, Alanen K, Nurmi M, Nees M, Härkönen P.

Int J Cancer. 2016 Jul 1;139(1):140-52. doi: 10.1002/ijc.30048. Epub 2016 Mar 12.

34.

Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care.

Riikonen J, Kaipia A, Petas A, Horte A, Koskimäki J, Kähkönen E, Boström PJ, Paananen I, Kuisma J, Santti H, Matikainen M, Rannikko A.

Scand J Urol. 2016 Jun;50(3):149-54. doi: 10.3109/21681805.2016.1142471. Epub 2016 Feb 16.

PMID:
26881411
35.

Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.

Alinezhad S, Väänänen RM, Tallgrén T, Perez IM, Jambor I, Aronen H, Kähkönen E, Ettala O, Syvänen K, Nees M, Kallajoki M, Taimen P, Boström PJ, Pettersson K.

Urol Oncol. 2016 Jun;34(6):255.e15-22. doi: 10.1016/j.urolonc.2015.12.014. Epub 2016 Feb 5.

PMID:
26857646
36.

Lymph node imaging in bladder cancer.

Salminen AP, Jambor I, Syvänen KT, Boström PJ.

Minerva Urol Nefrol. 2015 Dec 18. [Epub ahead of print]

PMID:
26684180
37.

[PSA and blood test diagnostics of prostate cancer].

Seikkula H, Pettersson K, Boström PJ.

Duodecim. 2015;131(17):1547-52. Review. Finnish.

PMID:
26548101
38.

Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression.

Saarinen I, Mirtti T, Seikkula H, Boström PJ, Taimen P.

PLoS One. 2015 Oct 15;10(10):e0140671. doi: 10.1371/journal.pone.0140671. eCollection 2015.

39.

Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.

Väänänen RM, Ochoa NT, Boström PJ, Taimen P, Pettersson K.

BMC Urol. 2015 Aug 21;15:88. doi: 10.1186/s12894-015-0077-7.

40.

Diffusion-weighted imaging of prostate cancer: effect of b-value distribution on repeatability and cancer characterization.

Merisaari H, Toivonen J, Pesola M, Taimen P, Boström PJ, Pahikkala T, Aronen HJ, Jambor I.

Magn Reson Imaging. 2015 Dec;33(10):1212-1218. doi: 10.1016/j.mri.2015.07.004. Epub 2015 Jul 26.

PMID:
26220861
41.

Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer.

Boström MM, Irjala H, Mirtti T, Taimen P, Kauko T, Ålgars A, Jalkanen S, Boström PJ.

PLoS One. 2015 Jul 21;10(7):e0133552. doi: 10.1371/journal.pone.0133552. eCollection 2015.

42.

Relaxation along fictitious field, diffusion-weighted imaging, and T2 mapping of prostate cancer: Prediction of cancer aggressiveness.

Jambor I, Pesola M, Merisaari H, Taimen P, Boström PJ, Liimatainen T, Aronen HJ.

Magn Reson Med. 2016 May;75(5):2130-40. doi: 10.1002/mrm.25808. Epub 2015 Jun 22.

PMID:
26094849
43.

Genomic Predictors of Outcome in Prostate Cancer.

Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR.

Eur Urol. 2015 Dec;68(6):1033-44. doi: 10.1016/j.eururo.2015.04.008. Epub 2015 Apr 23. Review.

44.

Erectile dysfunction cannot be used in primary screening of pre-diabetes.

Ettala OO, Korhonen PE, Syvänen KT, Kaipia AJ, Vahlberg TJ, Aarnio PT, Boström PJ.

Diabetes Res Clin Pract. 2015 Jun;108(3):e60-2. doi: 10.1016/j.diabres.2015.02.030. Epub 2015 Mar 3.

PMID:
25779867
45.

Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.

Järvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, Liukkonen T, Puolakka VM, Seppänen M, Tuhkanen K, Vaarala M, Viitanen J, Boström PJ; FinnBladder Group.

Eur Urol. 2015 Oct;68(4):611-7. doi: 10.1016/j.eururo.2015.02.022. Epub 2015 Mar 5.

PMID:
25748117
46.

Rotating frame relaxation imaging of prostate cancer: Repeatability, cancer detection, and Gleason score prediction.

Jambor I, Pesola M, Taimen P, Merisaari H, Boström PJ, Minn H, Liimatainen T, Aronen HJ.

Magn Reson Med. 2016 Jan;75(1):337-44. doi: 10.1002/mrm.25647. Epub 2015 Mar 2.

PMID:
25733132
47.

Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy.

Seikkula H, Syvänen KT, Kurki S, Mirtti T, Taimen P, Laato M, Boström PJ.

Urol Oncol. 2014 Nov 18. pii: S1078-1439(14)00353-6. doi: 10.1016/j.urolonc.2014.10.010. [Epub ahead of print]

PMID:
25456996
48.

Mathematical models for diffusion-weighted imaging of prostate cancer using b values up to 2000 s/mm(2) : correlation with Gleason score and repeatability of region of interest analysis.

Toivonen J, Merisaari H, Pesola M, Taimen P, Boström PJ, Pahikkala T, Aronen HJ, Jambor I.

Magn Reson Med. 2015 Oct;74(4):1116-24. doi: 10.1002/mrm.25482. Epub 2014 Oct 20.

PMID:
25329932
49.

European Association of Urology (@Uroweb) recommendations on the appropriate use of social media.

Rouprêt M, Morgan TM, Bostrom PJ, Cooperberg MR, Kutikov A, Linton KD, Palou J, Martínez-Piñeiro L, van der Poel H, Wijburg C, Winterbottom A, Woo HH, Wirth MP, Catto JW.

Eur Urol. 2014 Oct;66(4):628-32. doi: 10.1016/j.eururo.2014.06.046. Epub 2014 Jul 16.

50.

High-intensity physical activity, stable relationship, and high education level associate with decreasing risk of erectile dysfunction in 1,000 apparently healthy cardiovascular risk subjects.

Ettala OO, Syvänen KT, Korhonen PE, Kaipia AJ, Vahlberg TJ, Boström PJ, Aarnio PT.

J Sex Med. 2014 Sep;11(9):2277-84. doi: 10.1111/jsm.12618. Epub 2014 Jun 9.

PMID:
24909644

Supplemental Content

Loading ...
Support Center